British Journal of Anaesthesia, 2001, Vol. 87, No. 5 743-747
© 2001 The Board of Management and Trustees of the British Journal of Anaesthesia
Clinical Investigations |
Intrathecal ropivacaine for total hip arthroplasty: double-blind comparative study with isobaric 7.5 mg ml–1 and 10 mg ml–1 solutions
1Department of Anaesthetics and Intensive Care Medicine, The Queen’s University of Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast BT9 7BL, UK. 2Department of Anaesthetics, Musgrave Park Hospital, Stockmans Lane, Belfast, UK. 3AstraZeneca R&D, Sodertalje, Sweden*Corresponding author
This study was designed to evaluate the efficacy and safety of two concentrations of intrathecal ropivacaine, 7.5 and 10 mg ml–1, in patients undergoing total hip arthroplasty. One hundred and four patients, ASA I–III, were randomized to receive an intrathecal injection of one of two concentrations of isobaric ropivacaine. Group 1 (n=51) received 2.5 ml of 7.5 mg ml–1 ropivacaine (18.75 mg). Group 2 (n=53) received 2.5 ml of 10 mg ml–1 ropivacaine (25 mg). The onset and offset of sensory block at dermatome level T10, maximum upper and lower spread of sensory block and the onset, intensity and duration of motor block were recorded, as were safety data. Onset of motor and sensory block was rapid with no significant differences between the two groups. The median time of onset of sensory block at the T10 dermatome was 2 min (range 1–25 min) in Group 1 and 2 min (range 1–21 min) in Group 2. The median duration of sensory block at the T10 dermatome was 3.0 h (range 0.5–4.2 h) in Group 1 and 3.4 h (1.1–5.9 h) in Group 2 (P=0.002). The median duration of complete motor block was significantly prolonged (P<0.05) in Group 2 compared with Group 1 (1.9 vs 1.2 h, respectively). Anaesthetic conditions were excellent in all but one patient. Intrathecal ropivacaine, in doses of 18.75 and 25 mg, was well tolerated and provided effective anaesthesia for total hip arthroplasty.
Br J Anaesth 2001; 87: 743–7
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Sell, K. T. Olkkola, J. Jalonen, and R. Aantaa Minimum effective local anaesthetic dose of isobaric levobupivacaine and ropivacaine administered via a spinal catheter for hip replacement surgery Br. J. Anaesth., February 1, 2005; 94(2): 239 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. W. Fettes, G. Hocking, M. K. Peterson, J. F. Luck, and J. A. W. Wildsmith Comparison of plain and hyperbaric solutions of ropivacaine for spinal anaesthesia Br. J. Anaesth., January 1, 2005; 94(1): 107 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kallio, E.-V. T. Snall, M. P. Kero, and P. H. Rosenberg A Comparison of Intrathecal Plain Solutions Containing Ropivacaine 20 or 15 mg Versus Bupivacaine 10 mg Anesth. Analg., September 1, 2004; 99(3): 713 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kasaba, S. Onizuka, and M. Takasaki Procaine and Mepivacaine Have Less Toxicity In Vitro Than Other Clinically Used Local Anesthetics Anesth. Analg., July 1, 2003; 97(1): 85 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. O. Ogun, E. N. Kirgiz, A. Duman, S. Okesli, and C. Akyurek Comparison of intrathecal isobaric bupivacaine-morphine and ropivacaine-morphine for Caesarean delivery{dagger} Br. J. Anaesth., May 1, 2003; 90(5): 659 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Whiteside, D. Burke, and J. A. W. Wildsmith Comparison of ropivacaine 0.5% (in glucose 5%) with bupivacaine 0.5% (in glucose 8%) for spinal anaesthesia for elective surgery Br. J. Anaesth., March 1, 2003; 90(3): 304 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. McNamee, A. M. McClelland, S. Scott, K. R. Milligan, L. Westman, and U. Gustafsson Spinal anaesthesia: comparison of plain ropivacaine 5 mg ml-1 with bupivacaine 5 mg ml-1 for major orthopaedic surgery Br. J. Anaesth., November 1, 2002; 89(5): 702 - 706. [Abstract] [Full Text] [PDF]
|
|